FOUNDING ONCOTARGET EDITORIAL BOARD MEMBERS WIN 2019 NOBEL PRIZE
FOUNDING ONCOTARGET EDITORIAL BOARD MEMBERS WIN 2019 NOBEL PRIZE
NEW YORK, October 11, 2019 – The 2019 Nobel Prize in Physiology or Medicine has been awarded jointly to Oncotarget Editorial Board Members William G. Kaelin Jr., and Gregg L. Semenza for their discoveries of “how cells sense and adapt to oxygen availability.” The pair was named alongside UK physician-scientist Sir Peter J. Ratcliffe.
The Nobel Committee made the announcement Monday at the Karolinska Institute in Stockholm and the discoveries have implications for how we understand and potentially treat a range of conditions like cancer, heart attack, stroke and anemia. The Nobel Laureates identified molecular machinery that regulates the activity of genes in response to varying levels of oxygen.
Both William G. Kaelin and Gregg L. Semenza are founding members of Oncotarget, launched in 2010. Oncotarget is a weekly peer-reviewed open access bio-medical journal covering research on all aspects of oncology. The editors-in-chief are Mikhail (Misha) Blagosklonny and Andrei V. Gudkov.
Dr. Gudkov comes to Roswell Park from the Lerner Research Institute, Cleveland Clinic Foundation where he served as chair of the Department of Molecular Genetics and professor of biochemistry at Case Western University. He earned his doctoral degree in Experimental Oncology at the Cancer Research Center and a Doctorate of Science (D.Sci) in Molecular Biology at Moscow State University, Russia. He has authored or co-authored over 200 scientific articles and holds more than 30 patents. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.
Dr. Blagosklonny earned both his MD in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg, Russia. Dr. Blagosklonny subsequently relocated to the United States, where he was awarded the prestigious Fogarty Fellowship from the National Institutes of Health and worked several years at the National Cancer Institute, Bethesda, MD. Later he held a few positions before he was appointed Professor of Oncology at Roswell Park Cancer Institute in 2009. Dr. Blagosklonny is the author of over 200 articles. His research interests include cell cycle, anticancer therapeutics with an emphasis on translation of basic science into new anticancer strategies, cellular senescence and signal transduction. Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.
Gregg L. Semenza has published eight papers in Oncotarget. The papers include:
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Pang Y, Yang C, Schovanek J, Wang H, Bullova P, Caisova V, Gupta G, Wolf KI, Semenza GL, Zhuang Z, Pacak K. Oncotarget. 2017 Apr 4;8(14):22313-22324. doi: 10.18632/oncotarget.16224.
Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL. Oncotarget. 2016 Oct 4;7(40):64527-64542. doi: 10.18632/oncotarget.11743.
PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia. Luo W, Chen I, Chen Y, Alkam D, Wang Y, Semenza GL. Oncotarget. 2016 Feb 9;7(6):6379-97. doi: 10.18632/oncotarget.7142.
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, Hassan SJ, Asnaghi L, Handa JT, Merbs S, Eberhart CG, Semenza GL, Montaner S, Sodhi A. Oncotarget. 2016 Feb 16;7(7):7816-28. doi: 10.18632/oncotarget.6868.
HIF-1α and TAZ serve as reciprocal co-activators in human breast cancer cells. Xiang L, Gilkes DM, Hu H, Luo W, Bullen JW, Liang H, Semenza GL.Oncotarget. 2015 May 20;6(14):11768-78.
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL. Oncotarget. 2014 Dec 30;5(24):12509-27.
Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL. Oncotarget. 2014 Oct 15;5(19):8853-68.
Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Luo W, Semenza GL. Oncotarget. 2011 Jul;2(7):551-6.
Oncotarget is well known for publishing Nobel prize-winning papers. Editorial Board alumni include Endocrinologist Andrew Schally, a Nobel Prize winner in Physiology or Medicine (1977) published 12 papers in Oncotarget.
When people refer to contemporary medicine, accuracy plays one of the most crucial roles and people’s lives are directly dependent on it. Hence, any researches related to medicine are necessary to comply with the top standards. The issue today is that any recommendations of researches can be shared online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores higher than 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the required assistance to anyone, who has interest in oncology.
Blagosklonny
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and completed by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are willing to comprehend the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Hereby, the publication about melanoma, was utilized for citations in different news articles 69 times. In addition, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This article has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get useful scientific facts. Oncotarget is glad to have the chance to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.
https://www.pnas.org/content/early/2014/05/29/1405723111
Comments
Post a Comment